Get the Stockscreener App
4.14
3.24%
0.13
Pre-market:
4.14
Myriad Genetics Inc stock is traded at $4.14, with a volume of 1.96M.
It is up +3.24% in the last 24 hours and up +35.74% over the past month.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
See More
Previous Close:
$4.01
Open:
$4
24h Volume:
1.96M
Relative Volume:
0.98
Market Cap:
$395.99M
Revenue:
$829.00M
Net Income/Loss:
$-399.90M
P/E Ratio:
-0.9592
EPS:
-4.3159
Net Cash Flow:
$-23.20M
1W Performance:
+0.00%
1M Performance:
+35.74%
6M Performance:
-10.20%
1Y Performance:
-46.37%
1-Day Range:
$3.97
$4.255
1-Week Range:
$3.76
$4.255
52-Week Range:
$2.74
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.14 | 395.99M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - au.finance.yahoo.com
3 Reasons MYGN is Risky and 1 Stock to Buy Instead - finance.yahoo.com
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Myriad Genetics stock falls after guidance reset and weak Q2 figures - AD HOC NEWS
Myriad Genetics (MYGN) ex-CCO keeps stock-tied PSUs - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating the Challenges in Diagnostics & Research - DirectorsTalk Interviews
Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset - finance.yahoo.com
Form 8K Myriad Genetics Inc For: 17 September By Investing.com - Investing.com India
Myriad Genetics (NASDAQ: MYGN) Confirms 2026 Financial Outlook Amid Executive Commercial Leadership Shift - Kalkine Media
Myriad Genetics names Vishal Sikri as EVP, commercial - Medical Buyer
Myriad Genetics promotes Vishal Sikri to commercial chief By Investing.com - Investing.com South Africa
Myriad Genetics promotes Vishal Sikri to commercial chief - Investing.com
Myriad Genetics (NASDAQ: MYGN) swaps commercial chief but keeps 2026 outlook - Stock Titan
Myriad Genetics Appoints Vishal Sikri Executive Vice PresidentCommercial - finance.yahoo.com
A new commercial chief takes over at Myriad Genetics as his predecessor departs - Stock Titan
Myriad Genetics And 2 Other Penny Stocks To Consider - simplywall.st
Myriad Genetics at Wells Fargo conference: cancer focus amid pressure By Investing.com - Investing.com Canada
MYGN Maintained by UBS -- Price Target Lowered to $3.60 - GuruFocus
UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating - finance.yahoo.com
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN) - Yahoo Finance
Myriad Genetics Inc. (MYGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BlackRock arm now owns more than a tenth of Myriad Genetics (NASDAQ: MYGN) - Stock Titan
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter - Yahoo Finance
Why Myriad Genetics (MYGN) Stock Is Down Today - Yahoo Finance
Myriad Genetics stock downgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha
Myriad Genetics Stock Gets Double-Downgrade as Profitability Concerns Grow - Barron's
Myriad Genetics shares fall 7.1% after Piper Sandler downgrade - finance.yahoo.com
Why is Myriad Genetics stock tumbling today? By Investing.com - Investing.com South Africa
Why is Myriad Genetics stock tumbling today? - Investing.com
Piper Sandler cuts Myriad Genetics stock rating on profit concerns By Investing.com - Investing.com Nigeria
Piper Sandler Downgrades Myriad Genetics(MYGN.US) to Sell Rating, Cuts Target Price to $2 - Moomoo
Myriad Genetics Inc. (MYGN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference - GlobeNewswire
Myriad Genetics and Moderna Shares Plummet, What You Need To Know - finance.yahoo.com
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire
Burning Rock and Myriad Announce Global Strategic Technology Lice - The National Law Review
MYGN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Myriad Genetics Inc. - accessnewswire.com
MYGN Maintained by Stephens & Co. -- Price Target Lowered to $3. - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Marquis Who's Who Honors Ben Wheeler for Expertise in Finance and Healthcare - 24-7 Press Release Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake - Stock Titan
Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing - Stock Titan
Myriad Genetics Faces Multiple Investor Investigations - stl.news
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN - MarketBeat
3 Healthcare Stocks with Open Questions - Yahoo Finance
Price-Driven Insight from (MYGN) for Rule-Based Strategy - Stock Traders Daily
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):